Purchase this article with an account.
F. Audren, P. Massin, B. Haouchine, A. Erginay, J. Bergmann, A. Gaudric; Intravitreal Triamcinolone Acetonide of Triaminolone for the Treatment of Diabetic Refractory Macular Edema: Early Effect on Central Macular Thickness and Visual Acuity . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3964.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To determine, in eyes of diabetic patients with diffuse macular edema, the evolution of macular thickness and visual acuity during the first 4 weeks after intravitreal triamcinolone acetonide injection (TA). Methods: 33 eyes of 21 patients with mean age of 60.3 years (range: 37 to 70) and mean duration of diabetes of 15.4 years (range 4 to 30), were diagnosed with diabetic macular diffuse edema refractory to laser photocoagulation (mean duration of edema: 24.7 months, range 6 to 72; mean number of laser sessions: 2.3, range: 1 to 4). The central macular thickness (CMT) measured on optical coherence tomography (OCT) exceeded 300 µm. After informed consent, patients were injected with 4 mg TA through the inferior pars plana. During the first 4 weeks after injection, repeated central macular thickness measurements were performed (4 measurements in the 2 weeks after injection and then every week).Visual acuity (VA) was measured on Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at inclusion, day 14 and day 28. Results: Mean CMT (±SD) at inclusion was 552.5µm (+/-147.5) (range 323 to 958) and mean VA (±SD) was 42.2 (+/-12.9) (range 20 to 69). These values were 223.9 µm (+/-52.7) (range 138 to 323) and 47.8 (+/-12.6) (range 19 to 72) respectively15 days after injection, and 202.6 µm (+/- 40.9) (range 137 to 304) and 50.4 (+/-11.9) (range 24 to 70) respectively 28 days after injection. Differences between CMT at inclusion, day 14 and day 28 were significant (p<0.0001). Difference between VA at inclusion and day 14 was significant (p<0.001) but not between day 14 and day 28 (p=0.58). 16 (48%) patients had CMT inferior to 205 µm at day 14 and 21 (64%) at day 28. No correlation was found between initial VA and CMT, final VA and CMT, neither between visual gain and amplitude of CMT decrease. 10 patients required a topical anti-hypertensive treatment for an intraocular pressure superior over 25 mmHg. Conclusions: Intravitreal TA is rapidly effective in reducing CMT in diabetic diffuse macular edema. The visual gain is not correlated with the amplitude of the CMT decrease.
This PDF is available to Subscribers Only